June 17th 2024
Dr. Martin Reck presents the five year update of CheckMate 9LA (NCT03215706) and exploratory analysis of efficacy in patients who discontinued treatment due to treatment related adverse events in patients with metastatic non-small lung cancer.
January 31st 2022
Hossein Borghaei, DO, MS; and Martin Reck, MD, PhD, discuss factors that affect treatment selection in NSCLC, and the role of molecular and biomarker testing.